Kiran Mazumdar Shaw Picks Niece Claire Mazumdar to Steer Biocon's Next Phase

Her identified successor is her niece, Claire Mazumdar, a 37-year-old biotechnology professional who currently serves as founder and CEO of Bicara Therapeutics, a Nasdaq-listed company incubated by Biocon.

While no specific timeline has been set for the leadership transition, Claire is expected to assume a larger role in the near future.

“I am the sole owner of Biocon, and I need to make sure that I put it in good hands,” Mazumdar-Shaw said in an exclusive interaction, reported Fortune India. “I have seen my niece Claire as my successor, because I think she has proved to me that she can run a company.”

A pioneering figure in building India’s biotechnology ecosystem, Mazumdar-Shaw, 73, has transformed Biocon into a global biotech leader. She has no children, and her late husband, John Shaw, had served as vice chairman of the group.

Claire Mazumdar brings strong academic credentials to the role. She holds a degree in Biological Engineering from the Massachusetts Institute of Technology, an MBA from Stanford Graduate School of Business, and a PhD in Cancer Biology from Stanford School of Medicine.

Mazumdar-Shaw noted that Claire would also be supported by family members in the broader leadership ecosystem, including her brother, Eric Mazumdar, an artificial intelligence expert and professor at the California Institute of Technology, and her husband, Thomas Roberts, a noted oncologist at Massachusetts General Hospital. She added that other family members would be welcome to contribute meaningfully to the company’s future growth.

Mazumdar-Shaw founded Bicara Therapeutics in the United States to advance global clinical trials for a novel cancer platform based on bi-specific antibodies, designed to both shrink and eliminate tumours.

Claire, who previously worked with Third Rock Ventures and Rheos Medicines, has been leading Bicara since 2018. The company went public on Nasdaq in 2024 with a valuation exceeding $800 million and currently commands a market capitalisation of over $1.6 billion, even as its lead therapy targeting head and neck cancer remains under clinical development. Biocon now holds approximately a 10% stake in the company post-listing.

In recent months, Biocon has undertaken a major organisational restructuring, including merging its generics and biologics businesses, simplifying its corporate structure, and reducing debt. This strategic shift positions the company to leverage its biosimilars segment, which contributes around 60% of its revenue.

With 12 biosimilar products already commercialised and nearly 20 in development, Biocon aims to strengthen its standing as a global biosimilars leader. The merged Biocon Biologics was valued at $5.5 billion in 2025 and ranks among the top five biosimilar companies globally by revenue.

Mazumdar-Shaw emphasised that future growth will be anchored in technology, with a focus on differentiated biosimilars, novel biologics, and deeper integration of artificial intelligence across operations.

As part of the leadership transition, Shreehas Tambe, a long-time Biocon executive, assumed charge as CEO and Managing Director of the merged entity from April 1.

At Syngene International, another key group company, Siddharth Mittal will take over as Managing Director and CEO from July 1, succeeding Peter Bains. Mazumdar-Shaw noted that Syngene’s contract development and manufacturing (CDMO) capabilities remain underutilised—a gap the new leadership aims to address, alongside expanding AI-driven research capabilities.

Also Read: Pharma Education on Rise: Telangana Sees 96% B.Pharm Seat Fill-Up in TG EAPCET 2025